Skip to main navigation

Skip to content

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

Press Releases

Press Releases
Events & Presentations

2022
2021
2020
2019

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Dec 01, 2022

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

Nov 28, 2022

Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

Nov 21, 2022

Cognition Therapeutics Announces Closing of Public Offering

Nov 15, 2022

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022

Cognition Therapeutics Announces Pricing of Public Offering

Nov 10, 2022

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Oct 12, 2022

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

Oct 11, 2022

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

Sep 29, 2022

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

Sep 27, 2022

Cognition Therapeutics Announces Participation in September Investment Conferences

Sep 06, 2022

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 09, 2022

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes

Aug 04, 2022

Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

Aug 03, 2022

Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease

Jul 19, 2022

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Jun 23, 2022

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

Jun 08, 2022

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

Jun 02, 2022

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 13, 2022

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

May 04, 2022

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

May 03, 2022

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

Apr 25, 2022

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Apr 25, 2022

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

Apr 06, 2022

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

Mar 30, 2022

Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

Mar 22, 2022

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022

Mar 10, 2022

Cognition Therapeutics Announces Participation in March Investment Conferences

Mar 08, 2022

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

Feb 08, 2022

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

Jan 10, 2022

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

Jan 04, 2022

Terms of Use FCOI Policy Privacy Policy Contact us

Copyright© 2022 Cognition Therapeutics, Inc. All rights reserved